Castle Biosciences Inc CSTL
We take great care to ensure that the data presented and summarized in this overview for CASTLE BIOSCIENCES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CSTL
View all-
Black Rock Inc. New York, NY3.04MShares$102 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$72.7 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.79MShares$60 Million0.02% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.52MShares$50.7 Million2.16% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.47MShares$49.3 Million0.01% of portfolio
-
Nuveen, LLC Charlotte, NC957KShares$32 Million0.01% of portfolio
-
Braidwell LP Stamford, CT823KShares$27.5 Million1.08% of portfolio
-
State Street Corp Boston, MA724KShares$24.2 Million0.0% of portfolio
-
Aigh Capital Management LLC Baltimore, MD707KShares$23.7 Million2.66% of portfolio
-
Geode Capital Management, LLC Boston, MA699KShares$23.4 Million0.0% of portfolio
Latest Institutional Activity in CSTL
Top Purchases
Top Sells
About CSTL
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Insider Transactions at CSTL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 12
2026
|
Frank Stokes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,124
+12.2%
|
-
|
|
Jan 12
2026
|
Tobin W Juvenal Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,207
+8.75%
|
-
|
|
Jan 12
2026
|
Kristen M Oelschlager Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,207
+29.95%
|
-
|
|
Jan 12
2026
|
Derek J Maetzold Pres. & Chief Exec. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,219
+40.41%
|
-
|
|
Jan 06
2026
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Direct |
1,339
-4.34%
|
$53,560
$40.1 P/Share
|
|
Jan 05
2026
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Direct |
2,678
-7.99%
|
$101,764
$38.09 P/Share
|
|
Dec 22
2025
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Direct |
830
-2.42%
|
$33,200
$40.35 P/Share
|
|
Dec 17
2025
|
Kristen M Oelschlager Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
14,888
-54.71%
|
$580,632
$39.31 P/Share
|
|
Dec 17
2025
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Direct |
509
-1.46%
|
$20,360
$40.04 P/Share
|
|
Dec 16
2025
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Direct |
12,821
-26.88%
|
$487,198
$38.55 P/Share
|
|
Dec 15
2025
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Direct |
19,525
-14.81%
|
$761,475
$39.03 P/Share
|
|
Dec 11
2025
|
Tobin W Juvenal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
13,200
-13.2%
|
$488,400
$37.48 P/Share
|
|
Dec 11
2025
|
Frank Stokes Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,496
-8.2%
|
$166,352
$37.45 P/Share
|
|
Dec 10
2025
|
Frank Stokes Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,758
-4.79%
|
$104,804
$38.02 P/Share
|
|
Dec 10
2025
|
Frank Stokes Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,170
+9.68%
|
-
|
|
Dec 10
2025
|
Kristen M Oelschlager Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,552
-8.57%
|
$96,976
$38.02 P/Share
|
|
Dec 10
2025
|
Kristen M Oelschlager Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,170
+17.17%
|
-
|
|
Dec 10
2025
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,070
-8.28%
|
$230,660
$38.02 P/Share
|
|
Dec 10
2025
|
Derek J Maetzold Pres. & Chief Exec. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,424
+17.39%
|
-
|
|
Dec 10
2025
|
Tobin W Juvenal Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,490
-2.43%
|
$94,620
$38.02 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 354K shares |
|---|---|
| Grant, award, or other acquisition | 88.8K shares |
| Open market or private sale | 309K shares |
|---|---|
| Payment of exercise price or tax liability | 102K shares |